ALL KOREAN COSMETICS ARE HERE❤️
Change regional settings
ALL KOREAN COSMETICS ARE HERE❤️

for the treatment of angiopathy, glaucoma, cataracts
The isolated peptides prevent the development of retinal degeneration, normalize metabolism and prevent the development of retinal degeneration and optic nerve atrophy.
*In case of wet macular degeneration, edema, hemorrhages in the retina, only Visoluten and Retisil can be used. In retinal sclerosis (fibrosis), the use of retinal peptides is contraindicated.
| Revilab ML 03 | Prevent optic nerve atrophy |
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Cerluten №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Cerluten №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
| Retisil | Promotes a noticeable improvement in blood circulation and metabolism in the retina |
| Revilab SL 02 | It normalizes vascular permeability; reduces the appearance of local inflammatory reaction; stimulates repair processes in diseases and injuries of the retina. |
| Revilab ML 03 | Prevent optic nerve atrophy |
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Cerluten №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Cerluten №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
| Retisil | Promotes a noticeable improvement in blood circulation and metabolism in the retina |
| Revilab SL 02 | It normalizes vascular permeability; reduces the appearance of local inflammatory reaction; stimulates repair processes in diseases and injuries of the retina. |
| Title | Quantity | Directions for use | Mechanism of action | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||